

Open Access Correction



Correction: The 'FebBenz' approach for severe difficult-to-treat gout

Enrique Calvo-Aranda^{1,2,3*}[©], Claudia María Gómez-González^{1,3}[©], Fernando Pérez-Ruiz^{3,4,5}[©], Marta Novella-Navarro^{3,6}[©]

¹Rheumatology Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain

²Department of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain

³Crystal-induced Arthritis Study Group, Spanish Society of Rheumatology (GEACSER), 28001 Madrid, Spain

⁴Osakidetza, OSI EEC, Cruces University Hospital, Rheumatology Division, 48903 Barakaldo, Spain

⁵Department of Medicine, Medicine and Nursing School, University of the Basque Country, 48940 Leioa, Spain

⁶Rheumatology Department, Hospital Universitario La Paz, 28046 Madrid, Spain

*Correspondence: Enrique Calvo-Aranda, Rheumatology Department, Hospital Universitario Infanta Leonor, 28031 Madrid, Spain. ecalvoa@hotmail.com

Published: July 7, 2025

Cite this article: Calvo-Aranda E, Gómez-González CM, Pérez-Ruiz F, Novella-Navarro M. Correction: The 'FebBenz' approach for severe difficult-to-treat gout. Explor Musculoskeletal Dis. 2025;3:100796. https://doi.org/10.37349/emd.2025.100796

Correction to "The 'FebBenz' approach for severe difficult-to-treat gout" by Calvo-Aranda E, et al. Explor Musculoskeletal Dis. 2025;3:100793. DOI: 10.37349/emd.2025.100793

The authors have recognized an error to the published paper:

In Figure 1, the data corresponding to 6m (FBX monotherapy) was set incorrectly. The corrected figure is given below.

The authors apologize for any inconvenience caused to the readers by the mistake. The conclusions made in the original publication were based on the correct data, and as such they are unaffected by the errors made.

© The Author(s) 2025. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.





Figure 1. Changes in serum urate during sequential combination therapy. At 12 months, SUA had decreased significantly (Δ = 7.4 mg/dL; 95% CI, 6–8.7; *p* < 0.01), with FBX alone contributing to a Δ of 5.4 mg/dL and BNZ an additional Δ of 2.1 mg/dL (both *p* < 0.01). (a) Reduction in SUA after initial uptitration of FBX over 6 months. Data are expressed as mean ± SD. (b) Additional decrease in SUA after addition of BNZ. SUA: serum urate; FBX: febuxostat; BNZ: benzbromarone; CI: confidence interval; SD: standard deviation